stockportfolio.pro
Stocks / MDGL vs SMMT
MDGL vs SMMT
Madrigal Pharmaceuticals, Inc. and Summit Therapeutics Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Madrigal Pharmaceuticals, Inc. (MDGL) | Summit Therapeutics Inc. (SMMT) | |
|---|---|---|
| Market cap | $11.0B | $10.4B |
| Revenue (latest FY) | $958.40M | $0 |
| Net income (latest FY) | $-288.28M | $-1.08B |
| Revenue growth (5y CAGR) | — | — |
| Net margin | -30.1% | — |
| Return on equity | -47.8% | -163.9% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open MDGL — free Open SMMT — freeFrequently asked questions
Which is bigger, MDGL or SMMT?
Madrigal Pharmaceuticals, Inc. is larger by market capitalization — $11.0B versus $10.4B.
Which grows faster, MDGL or SMMT?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.